Biohaven Completes Enrollment in Pivotal Study for Opakalim Treating Focal Epilepsy

Biohaven Completes Enrollment in Pivotal Opakalim Study

Biohaven Ltd., a pioneering biopharmaceutical company, has announced the successful completion of recruitment for its pivotal Phase 2/3 study, RISE3, which is focused on the efficacy of opakalim in treating patients with refractory focal epilepsy. This major milestone in clinical research signifies a critical step towards potentially offering new options for individuals whose seizures remain uncontrolled despite existing treatments.

The RISE3 study, which evaluates opakalim's performance as a selective Kv7.2/7.3 channel activator, is crucial for addressing the unmet medical needs faced by many epilepsy patients. The study is designed to compare the results of participants receiving opakalim versus those given a placebo, all while continuing their stable background regimen of antiseizure medications (ASMs).

Background of Opakalim

Opakalim is being developed to provide seizure control with minimized side effects common to traditional antiseizure medications. Often, existing medications can lead to dizziness, drowsiness, and memory issues, severely impacting patients' quality of life. In contrast, opakalim aims to deliver a treatment solution that can effectively manage seizures without these burdensome side effects.

Recent presentations have revealed promising data regarding opakalim's efficacy. A notable 54% of participants receiving a daily dose of 75 mg opakalim experienced a significant reduction in their seizure frequency during an open-label extension study. Additionally, the safety profile shows a notably lower rate of nervous system adverse events compared to traditional ASMs.

Study Design and Expectations

During the 8-week treatment period of the RISE3 study, adult patients experiencing refractory focal onset seizures—characterized by a history of at least four seizures per month despite taking up to three ASMs—were randomly assigned to receive either opakalim or a placebo. The primary goal of this study is to measure the change in seizure frequency over time, which will offer insights into the potential effectiveness of opakalim compared to existing options.

Top-line results from the RISE3 study are anticipated in the second half of 2026, which could have significant implications for the future of epilepsy treatment. Jason Lerner, the Medical Director for Research and Development at Biohaven stated that reaching this enrollment milestone is a significant accomplishment, paving the way for a potential new treatment alternative that does not compromise patients' quality of life.

Importance of Participation

Biohaven extends its gratitude to all participants involved in the study along with the sites responsible for the trial's success. The high enrollment completion rates, along with an impressive rollover of nearly 95% of participants into the open-label extension study, demonstrate the supportive environment established for those partaking in the trial.

As research continues, the epilepsy community is eager for the outcomes of the RISE3 study and the potential advancement of opakalim, which could bring hope to those living with challenging seizure disorders. With stringent safety protocols and a focus on quality of life, Biohaven strives to deliver innovative and effective treatment solutions focused on improving patient outcomes in neurological health.

The journey toward developing opakalim is a testament to Biohaven's dedication to creating impactful therapies and addressing critical needs within the field of epilepsy management. Stakeholders await the comprehensive data from ongoing studies to generate new possibilities for patients and their families while addressing one of healthcare's formidable challenges.